The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genentech
Stock and Other Ownership Interests - Roche
Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.
 
Herbert Hurwitz
No Relationships to Disclose
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - Genentech (Inst)
 
Howard A. Burris
No Relationships to Disclose
 
Razelle Kurzrock
Leadership - CureMatch; Novena; RScueRx
Stock and Other Ownership Interests - Actuate Therapeutics; CureMatch; Novena; RScueRx
Honoraria - AACR; AACR; Actuate Therapeutics; Casdin Capital; Casdin Capital; Casdin Capital; Casdin Capital; Cedars-Sinai; Frankel Group; Global Biomarkers Consortium; Janssen; Jubilant Biosys; NCCN; Northwestern University; NXT Health Strategies; NXT Health Strategies; Segal Cancer Center; Seminars in Oncology; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; The Dedham Group; UCSD Genomics Program Talk; Yale Cancer Center
Consulting or Advisory Role - AACR; Actuate Therapeutics; CTRC-EAB San Antonio; Janssen; Jubilant Biosys; Merck; SAIC NCI CCCT IDSE; Sequenom
Research Funding - Centocor Ortho Biotech; EMD Serono; EMD Serono; EMD Serono; Exelixis; Foundation Medicine; Genentech Mypath; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; Merck; Merck; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sequenom; XBiotech
Patents, Royalties, Other Intellectual Property - Patent; Patent; Patent; Patent
Travel, Accommodations, Expenses - AACR; AACR; Association of American Cancer Institutes; Caris Centers of Excellence; Caris Centers of Excellence; EMD Serono; EMD Serono & Quintiles; EMD Serono & Quintiles; Gateway Research Advisory Committee; Gateway Research Advisory Committee; Global Biomarkers Consortium; Guardant Health; ICRP; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma
 
Christopher Sweeney
Stock and Other Ownership Interests - BIND Biosciences; Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BIND Biosciences; Genentech/Roche; Janssen Biotech; Sanofi
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Janssen Biotech (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Genentech; Inflection Biosciences; Novartis; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; CytomX Therapeutics; Debiopharm Group; Genentech; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem
 
Ari M. Vanderwalde
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Caris Life Sciences; Genentech/Roche
Research Funding - Amgen; AstraZeneca; Genentech/Roche; Lilly; Merck; Millennium; Polynoma
 
David R. Spigel
Stock and Other Ownership Interests - Foundation Medicine; Illumina
Consulting or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
Speakers' Bureau - Novartis
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BIND Biosciences (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); ImClone Systems (Inst); Immunogen (Inst); Lilly (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Novartis; Pfizer
 
Ron Bose
Honoraria - Genentech; Novartis
Consulting or Advisory Role - Genentech
 
Marwan Fakih
Honoraria - Sirtex Medical
Consulting or Advisory Role - Amgen; Sirtex Medical
Speakers' Bureau - Sirtex Medical
Research Funding - Amgen (Inst); Novartis (Inst)
 
Charles Swanton
Stock and Other Ownership Interests - Apogen Biotechnologies; Epic Sciences
Honoraria - Boehringer Ingelheim; Celgene; GlaxoSmithKline; Lilly; Ono Pharmaceutical; Roche; SERVIER
Research Funding - Boehringer Ingelheim
 
Shuangli Guo
No Relationships to Disclose
 
Coen Bernaards
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Mary Stanley Beattie
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Travel, Accommodations, Expenses - Genentech/Roche
 
Nicolas Sommer
No Relationships to Disclose
 
John D. Hainsworth
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Celgene (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Novartis (Inst)